IMO Ken made some serious and avoidable mistakes, which markedly reduced the chances of success in the last trial. But he didn't achieve it on his own so I guess the blame gets shared. Could the company have some other revenue generation from a diabecell sideline? Maybe. Otherwise I can't see how the new director proposal could contribute anything. What's the case for doing it?
Ann: NEW 2022 Annual General Meeting Date, page-28
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $4.046K | 577.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 5025067 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 950168 | 3 |
View Market Depth
| Last trade - 14.15pm 17/10/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |